title: [Lead-in in triple therapy for hepatitis C virus. Is it necessary or not?].
authors.affiliation: Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
authors.forename: Alberto
authors.initials: A
authors.lastname: Lué
authors.affiliation: Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España. Electronic address: masimonmarco@gmail.com.
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Simón Marco
mesh_terms: D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D060828:Induction Chemotherapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D009842:Oligopeptides / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline; C417083:peginterferon alfa-2b